Skip to content
BIO IP Conference looks at academics and perceptions of IP
The post-COVID era has been especially hard on patent lawyers working in the ...
Read More
Patient advocates urge action on PPRV to help fight rare disease
Patient advocates retold emotional stories of lives saved, changed—or at risk—as they discussed ...
Read More
Who invented what? BIO IP panel tackles joint inventorship
We sometimes imagine the inventor of a patent as a lone vanguard leading ...
Read More
Bayh-Dole at 45: Still an engine for innovation
A researcher working in a university lab makes a discovery that could lead ...
Read More
House passes BIO-backed legislation to increase access to capital
Legislation to free up capital for small innovative firms by removing regulatory barriers ...
Read More
Charlotte emerging as a global leader in health care innovation and med tech
Historically, Charlotte has been recognized as a major U.S. financial hub. Now, the ...
Read More
EDITORS' CHOICE
BIO CEO testifies in hearing highlighting PBMs’ impact on drug prices
Pharmacy benefit managers (PBMs) were identified as a major driver behind higher prescription drug costs in a congressional hearing that featured testimony from BIO President ...
Read More
LATEST NEWS
BIO's View
The hidden layer of PBMs: What a recent investigation reveals
With health care affordability a top concern for many Americans, pharmacy benefit managers (PBMs) continue to stand at the center of the debate. Working with ...
BIO's View
Nearly half of Americans say insurers’ rules on access delayed, denied, or altered care
Americans are frustrated with the health care system for two reasons. First, it costs too much. But—second—it provides too little. While most of the dialogue ...
BIO Events
BIG Summit: Experts see signs of M&A momentum in 2026
We could be in for another big year of biotech M&A. A busy 2025, in both licensing and M&A in biopharma, saw over 4,000 deals ...
BIO Events
BIG Summit: Seeking opportunities while navigating risks of global trade
China is becoming an increasingly influential player in the global biotech market. More than a third of U.S. licensing deals this year have involved assets ...
Federal Policy
BIO Patient Advocacy Coffee Chat: Act now to be heard on CMS drug pricing
The Medicare drug price “negotiation” process has entered its third year, with some evolution but continued complexity for patients and patient organizations. This year, 15 ...
HEALTH
Welcome, John F. Crowley!
Get to know John F. Crowley, the new President and CEO of the Biotechnology Innovation Organization (BIO), in our exclusive interview.
Federal Policy
State Policy
Charlotte emerging as a global leader in health care innovation and med tech
Historically, Charlotte has been recognized as a major U.S. financial hub. Now, the city is making significant strides in another ...
Read More
International
Bio's View
The hidden layer of PBMs: What a recent investigation reveals
With health care affordability a top concern for many Americans, pharmacy benefit managers (PBMs) continue to stand at the center ...
Read More
